This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Dry Eye Discussions: New Treatments for Meibomian Gland Dysfunction (CME/CE)
MedEdicus Podcasts
29 minutes
2 years ago
Dry Eye Discussions: New Treatments for Meibomian Gland Dysfunction (CME/CE)
Access the disclosures, evaluation, and your CME credit via: https://courses.mededicus.com/content/discussing-evaporative-dry-eye-updates-diagnosis-and-new-treatments-cmece-podcast Creating evidence-based treatment plans for those with DED requires a nuanced understanding of the role of tear film evaporation in eye health. This podcast features discussions between Leslie E. O’Dell, OD, FAAO and Lisa M. Nijm, MD, JD on evaporation in DED, gland expression, and new treatments. The activity als...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
